Table 2.
Description of main patient and clinical factors used for evaluation of the models and formula
| Studya/geographic area | Europe —otherb | Europe—Scandinavia | Europe—United Kingdom | Netherlands— BOSOM | Netherlands— EMC | Netherlands— NCR | United States and Australia |
|---|---|---|---|---|---|---|---|
| N | 15,183 | 12,928 | 11,921 | 3760 | 3390 | 83,138 | 2436 |
| Age at first diagnosis, years (%) | |||||||
| < 30 | 152 (1.0) | 46 (0.4) | 156 (1.3) | 108 (2.9) | 46 (1.4) | 388 (0.5) | 41 (1.7) |
| 30–39 | 1252 (8.2) | 489 (3.8) | 1811 (15.2) | 842 (22.4) | 374 (11.0) | 4241 (5.1) | 494 (20.3) |
| 40 + | 13,779 (90.8) | 12,393 (95.9) | 9954 (83.5) | 2810 (74.7) | 2970 (87.6) | 78,509 (94.4) | 1901 (78.0) |
| Age at first birth = unknown (%) | 15,183 (100.0) | 12,928 (100.0) | 11,921 (100.0) | 3760 (100.0) | 3390 (100.0) | 83,138 (100.0) | 2436 (100.0) |
| Family history (%) | |||||||
| Yes | 2123 (14.0) | 818 (6.3) | 1371 (11.5) | 737 (19.6) | 591 (17.4) | 0 (0.0) | 319 (13.1) |
| No | 8057 (53.1) | 3158 (24.4) | 8210 (68.9) | 1177 (31.3) | 2482 (73.2) | 0 (0.0) | 1498 (61.5) |
| Unknown | 5003 (33.0) | 8952 (69.2) | 2340 (19.6) | 1846 (49.1) | 317 (9.4) | 83,138 (100.0) | 619 (25.4) |
| First BC type = Pure invasive (%) | 15,183 (100.0) | 12,928 (100.0) | 11,921 (100.0) | 3760 (100.0) | 3390 (100.0) | 83,138 (100.0) | 2436 (100.0) |
| Breast density = unknown (%) | 15,183 (100.0) | 12,928 (100.0) | 11,921 (100.0) | 3760 (100.0) | 3390 (100.0) | 83,138 (100.0) | 2436 (100.0) |
| ER status (%) | |||||||
| Negative | 3387 (22.3) | 1746 (13.5) | 1718 (14.4) | 896 (23.8) | 842 (24.8) | 14,591 (17.6) | 445 (18.3) |
| Positive | 10,071 (66.3) | 9401 (72.7) | 7175 (60.2) | 2024 (53.8) | 2427 (71.6) | 64,790 (77.9) | 1572 (64.5) |
| Unknown | 1725 (11.4) | 1781 (13.8) | 3028 (25.4) | 840 (22.3) | 121 (3.6) | 3757 (4.5) | 419 (17.2) |
| High-risk pre-neoplasia = unknow n (%) | 15,183 (100.0) | 12,928 (100.0) | 11,921 (100.0) | 3760 (100.0) | 3390 (100.0) | 83,138 (100.0) | 2436 (100.0) |
| Anti-estrogen therapy (%) | |||||||
| Yes | 7868 (51.8) | 6434 (49.8) | 8712 (73.1) | 809 (21.5) | 1559 (46.0) | 40,214 (48.4) | 363 (14.9) |
| No | 4570 (30.1) | 1947 (15.1) | 2046 (17.2) | 2739 (72.8) | 1821 (53.7) | 42,924 (51.6) | 8 (0.3) |
| Unknown | 2745 (18.1) | 4547 (35.2) | 1163 (9.8) | 212 (5.6) | 10 (0.3) | 0 (0.0) | 2065 (84.8) |
| CBC cumulative incidence (%) | |||||||
| 3-year (95% CI) | 1.0 (0.8–1.2) | 0.7 (0.5–0.9) | 0.5 (0.3–0.7) | 1.7 (1.3–2.1) | 1.7 (1.2–2.1) | 1.3 (1.2–1.4) | 1.8 (0.8–2.8) |
| 5-year (95% CI) | 1.6 (1.4–1.9) | 1.0 (0.8–1.3) | 1.0 (0.8–1.3) | 3.0 (2.5–3.6) | 2.6 (2.1–3.2) | 2.4 (2.3–2.5) | 2.8 (1.7–3.8) |
| 10-year (95% CI) | 3.5 (3.1–3.9) | 2.1 (1.7–2.4) | 1.3 (1.0–1.5) | 5.5 (4.7–6.2) | 5.7 (4.9–6.6) | 4.6 (4.5–4.8) | 4.1 (3.0–5.3) |
More details about the main patient and clinical characteristics by study are available in the supplementary information of [5]
BOSOM Breast Cancer Outcome Study of Mutation carriers, EMC Erasmus Medical Center, NCR Netherlands Cancer Registry, BC breast cancer, ER estrogen receptor, CBC contralateral breast cancer, CI confidence interval
a
The studies denoted with Europe and United States and Australia are part of the Breast Cancer Association Consortium
b
Europe—other geographic area included studies from Belgium (1), Germany (2), Netherlands (2) and Poland (2)